GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Khiron Life Sciences Corp (OTCPK:KHRWF) » Definitions » Net Current Asset Value

Khiron Life Sciences (Khiron Life Sciences) Net Current Asset Value : $0.00 (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Khiron Life Sciences Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Khiron Life Sciences's net current asset value per share for the quarter that ended in Sep. 2022 was $0.00.

The historical rank and industry rank for Khiron Life Sciences's Net Current Asset Value or its related term are showing as below:

During the past 10 years, the highest Price-to-Net-Current-Asset-Value Ratio of Khiron Life Sciences was 20.00. The lowest was 0.76. And the median was 3.24.

KHRWF's Price-to-Net-Current-Asset-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.15
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Khiron Life Sciences Net Current Asset Value Historical Data

The historical data trend for Khiron Life Sciences's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Khiron Life Sciences Net Current Asset Value Chart

Khiron Life Sciences Annual Data
Trend May12 May13 May14 May15 May16 May17 Dec18 Dec19 Dec20 Dec21
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Khiron Life Sciences Quarterly Data
Nov17 Feb18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Khiron Life Sciences's Net Current Asset Value

For the Drug Manufacturers - Specialty & Generic subindustry, Khiron Life Sciences's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Khiron Life Sciences's Price-to-Net-Current-Asset-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Khiron Life Sciences's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Khiron Life Sciences's Price-to-Net-Current-Asset-Value falls into.



Khiron Life Sciences Net Current Asset Value Calculation

Khiron Life Sciences's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2021 is calculated as

Net Current Asset Value Per Share(A: Dec. 2021 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(18.573-6.988-0-0)/0
=N/A

Khiron Life Sciences's Net Current Asset Value (NCAV) per share for the quarter that ended in Sep. 2022 is calculated as

Net Current Asset Value Per Share(Q: Sep. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(13.739-8.508-0-0)/0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Khiron Life Sciences  (OTCPK:KHRWF) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Khiron Life Sciences Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Khiron Life Sciences's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Khiron Life Sciences (Khiron Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5
Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.